

Andrew N. Ming-Lum, PhD

Associate



T (617) 248-4752
aminglum@choate.com

Practice Areas

Intellectual Property Protection
Life Sciences

Education

University of British Columbia Faculty of Law
JD (2015)

University of British Columbia
PhD (2012) Experimental Medicine

Queen's University
BS (2002) Life Sciences, with honors

Admissions

Massachusetts
U.S. Patent & Trademark Office
(Limited Recognition)
Law Society of British Columbia

Dr. Andrew Ming-Lum utilizes his extensive knowledge of immunology, molecular biology, and biochemistry to help clients build and protect their intellectual property portfolios. His work includes the preparation and prosecution of patent applications in a variety of life science technologies, including large molecule biologics, immunotherapies, small molecule pharmaceuticals, vaccines, medical diagnostic methods, medical devices, and molecular and biochemical research tools and reagents.

Andrew is also experienced in preparing freedom to operate and patentability analyses, patent landscape search and analyses, validity and infringement analyses, performing intellectual property due diligence, and patent portfolio strategy and development.

Publications and Presentations

- “Interleukin-10 and Small Molecule SHIP1 Allosteric Regulators Trigger Anti-inflammatory Effects through SHIP1/STAT3 Complexes,” co-author, *iScience*, 2020
- “Chapter 13: Public Policy Options to Incent Innovation,” co-author, *The Business of Innovation: Intellectual Property Transactions and Strategies in the New Economy*
- “Interleukin-10 inhibits lipopolysaccharide induced miR-155 precursor stability and maturation,” co-author, *PLoS*
- “Interleukin-10 inhibits lipopolysaccharide-induced tumor necrosis factor-alpha translation through a SHIP1-dependent pathway,” co-author, *Journal of Biological Chemistry*
- “A Pleckstrin Homology-Related domain in SHIP1 mediates membrane localization in FcGamma-receptor induced phagocytosis,” first author, *FASEB Journal*
- “Innate immunity immunomodulation via SHIP activation,” presenter, XXIII International Congress of the Transplantation Society
- “Relation'SHIP' between the PI 3-Kinase Pathway and Early Phase regulation of IL-10 α production,” presenter, Keystone Symposia
- “Small-molecule regulation of macrophage activation,” presenter, 40th Annual Meeting of the Society of Leukocyte Biology
- “Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells,” first author, *Blood*
- “Negative regulation of inflammation via SHIP activation,” presenter, Institut Pasteur

- “Small-molecule agonist regulation of immune cell activation,” presenter, Transplantation Society / CST Basic Science Symposium
- “Proteasome-mediated proteolysis of the interleukin-10 receptor is important for signal downregulation,” co-author, *Journal of Interferon and Cytokine Research*
- “Divergent mechanisms utilized by SOCS3 to mediate interleukin-10 inhibition of tumor necrosis factor alpha and nitric oxide production in macrophages,” co-author, *Journal of Biological Chemistry*